J. Van Noord (Em Heerlen, The Netherlands), P. M. A. Calverley (Liverpool, UK)
Serum level of VIP (vasoactive intestinal polypeptide) in patients with COPD in stable state and during exacerbation
L. Corkovic, N. Kostic (Belgrade, Yugoslavia)
|  |
Pulmonary thromboembolism as the cause of death in patients with COPD
V. K. Ostric, Z. Kosjerina, S. Zivojinovic (Sremska Kamenica, Yugoslavia)
| |
Right ventricular functional peculiarities at various stages of COPD
R. R. Frangulyan, L. L. Janjapanyan (Yerevan, Armenia)
| |
Cardiopulmonary effects of long-term bronchodilator therapy in patients with chronic obstructive bronchitis
T. Onyshchenko, T. Pertseva, N. Anosova, L. Konopkina (Dniepropetrovsk, Ukraine)
| |
Prevalance of chlamydia, mycoplasma, legionella and influenza A antibodies in acute exacerbation of COPD
K. Uzun, B. Ozbay, T. Buzgan, I. Zehir, S. Andic, C. Sezgi, O. Evigen (Van, Turkey)
| |
Atrophic bronchopathy as a phenomenon of atrophy bronchial epithelium
L. A. Naumova, I. Y. Belov, G. I. Nepomnyashchikh (Novosibirsk, Russia)
| |
A double-blind trial of hyperosmolar saline as an adjunt to phsiotherapy in patients with bronchiectasis
F. Kellett, R. M. Niven, J. Redfern (Manchester, United Kingdom)
| |
Smoking reduction and hospitalization from COPD: a Danish population study
N. S. Godtfredsen, M. Osler, J. Vestbo, E. Prescott (Copenhagen, Hvidovre, Denmark)
| |
Nutritional status and health-related quality of life in patients with chronic obstructive pulmonary disease (COPD)
J. J. Soler, L. Sanchez, M. A. Martinez, P. Roman, M. Perpiña (Valencia, Spain)
| |
Therapeutic saline inhalation: effects on lung function and dyspnoea in patients with chronic obstructive airway diseases
M. Behnke, M. Bauspiess, B. Merkt, I. Robinson, D. Kirsten, R. A. Jörres, H. Magnussen (Grosshansdorf, Germany)
| |
Plasma orexin-A level and body composition in patients with chronic obstructive pulmonary disease
T. Matsumra, K. Sekizawa, M. Nakayama, A. Naitoh, K. Kadono, K. Kamahara, T. Homma (Tsukuba, Ibaraki, Japan)
| |
Long-term treatment with oxytropium bromide does not affect uroflowmetry in male patients with COPD. Preliminary results
R. De Tullio, G. Giocoli Nacci, A. Marano, E. Gatta (Bari, Italy)
| |
Social support and health status in chronic lung disease
D. Inal Ince, S. Savci, T. Selcuk, H. Arikan (Ankara, Turkey)
| |
Day to day variation in bronchodilator reversibility in stable COPD
P. M. A. Calverley, S. Burge, S. Spencer, J. Anderson, P. W. Jones (Liverpool, Birmingham, London, United Kingdom)
| |
Classification of COPD patients by using a standardized diagnostic questionnaire
M. Chiostri, S. M. Romano, G. Camiciottoli, N. M. Maluccio, F. Lavorini, G. A. Fontana, M. Pistolesi (Florence, Italy)
| |
Tiotropium: COPD exacerbations and decline in FEV1
R. Pauwels, J. P. H. M. Creemers, S. S. Menjoge, S. Kesten, P. J. G. Cornelissen (Ghent, Belgium; Eindhoven, Alkmaar, The Netherlands; Ridgefield, United States Of America)
| |
Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD?
J. A. van Noord, J. J. Smeets, S. S. Menjoge, S. Kesten, P. J. G. Cornelissen (Heerlen, Alkmaar, The Netherlands; Ridgefield, United States Of America)
| |
A preliminary meta-analysis of long-term inhaled steroids for stable chronic obstructive pulmonary disease
M. B. Stanbrook, D. N. Juurlink (Toronto, Canada)
| |
The assessment of thyroid functions in patients with COPD
O. Okutan, Z. Kartaloglu, M. E. Onde, E. Bozkanat, E. Kunter (Istanbul, Turkey)
| |
Quality of life in patients with chronic obstructive pulmonary disease (COPD) and long-term oxygen therapy (LTOT)
L. Galan, C. Castillo, G. Saez, M. Ortega, E. Granados, M. Guillamón, J. M. Díez, S. Merlos, S. López, J. Alvarez (Granada, Spain)
| |